<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151262">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01786889</url>
  </required_header>
  <id_info>
    <org_study_id>ANGI HE-1110</org_study_id>
    <nct_id>NCT01786889</nct_id>
  </id_info>
  <brief_title>Identification, Molecular Epidemiology Angiosarcoma of the Liver France</brief_title>
  <acronym>ANGIHE</acronym>
  <official_title>Identification, Molecular Epidemiology Angiosarcoma of the Liver France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <authority>France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the feasibility of identifying incident cases of
      angiosarcoma of the liver from the network NetSarc
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Feasibility of identifying incident cases of angiosarcoma liver from the network NetSarc</measure>
    <time_frame>At month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feasibility of identifying incident cases of angiosarcoma of the liver (ASF) from the network NetSarc: number of sheets indicated and returned to the Promoter. 30 cases are expected, the cumulative number of incident cases will be measured over a period of 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prospective surveillance in France</measure>
    <time_frame>At month 36</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of occupational risk factors and environmental</measure>
    <time_frame>At month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be collected using a questionnaire with:
Exhaustive search of all occupational and environmental exposures as known or suspected risk factors for ASF
Reconstruction of residential history and haunts each case by means of a collection of successive addresses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of biomarkers associated with human exposure Environmental old and new to vinyl chloride monomer</measure>
    <time_frame>At 36 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Research suggestive of carcinogenesis related to CVM (identified in animal models and cohorts of workers exposed) biomarkers will be made by biological testing (blood and urine) adducts éthénobases kind resulting from the reaction of metabolites with CVM DNA and specific gene mutations k-ras and p53. Exposure to arsenic via the determination of Arsenic urinaire.sera sought.
The p53 and K-ras genes are also sequences from initial diagnostic biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the amount of vinyl chloride monomèredans successive addresses or nearby for cases without occupational exposure identified</measure>
    <time_frame>At month 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data will be collected using a questionnaire with:
- Assessment of the amount of vinyl chloride monomer (VCM) in successive addresses or nearby for cases without occupational exposure identified</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Angiosarcoma</condition>
  <arm_group>
    <arm_group_label>questionnaire, telephone interview and sample</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood and urine</intervention_name>
    <arm_group_label>questionnaire, telephone interview and sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <arm_group_label>questionnaire, telephone interview and sample</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Telephone interview</intervention_name>
    <arm_group_label>questionnaire, telephone interview and sample</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with angiosarcoma of the liver (angiosarcoma immediately multifocal
             allowed) diagnosed by histology from the start of the study

          -  The patient's written Consent

        No exclusion criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J-Marc NABOLTZ, MD, PhD</last_name>
      <phone>0473278482</phone>
      <email>jm.naboltz@cjp.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques-Olivier BAY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale DUCRAY-LONGERAS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges François</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine TIAGO, CRA</last_name>
      <phone>0345348051</phone>
      <email>stiago@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas ISAMBERT, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle DESMOULINS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas PENEL, Dr</last_name>
      <phone>+33(0)3 20 29 59 20</phone>
      <email>n-penel@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas PENEL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique HOGUET, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J-Yves BLAY, MD, PhD</last_name>
      <phone>04 78782888</phone>
      <email>jean-yves.blay@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle RAY-COQUART, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josiane ONEZIME, CRA</last_name>
      <phone>0491384605</phone>
      <email>josiane.onezime@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Florence DUFFAUD, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien SALAS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thanh Khoa HUYNH, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRLCC Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J-Pierre BLEUSE, MD</last_name>
      <phone>0467672344</phone>
      <email>jean-pierre.bleuse@montpellier-unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Didier CUPISSOL, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J-Pierre LOTZ, MD</last_name>
      <phone>01 56 01 60 58</phone>
      <email>jean-pierre.lotz@tnn.ap-hop-paris.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre LOTZ, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien</name>
      <address>
        <city>St PRIEST EN JAREZ</city>
        <zip>42 270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Séverine MARCHAND, CRA</last_name>
      <phone>0477127444</phone>
      <email>severine.marchand@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier COLLARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J-Emmanuel KURTZ, MD, PhD</last_name>
      <phone>0388128436</phone>
      <email>j-emmanuel-kurtz@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>J-Emmanuel KURTZ, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine CHEVREAU, MD</last_name>
      <phone>05 61 42 41 74</phone>
      <email>chevreau.christine@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Christine CHEVREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu / Hopital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina MALIVOIR, CRA</last_name>
      <phone>0247478625</phone>
      <email>b.malivoir@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Claude LINASSIER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Berengère NARCISO, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemangiosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
